In this comprehensive review, we focus on the mechanisms underpinning VEGF-mediated immunosuppression and how these can be therapeutically abrogated by combined VEGF and PD-(L)1 blockade in patients with cancer to augment antitumor immunity. The gene discussed is CD274; the disease is cancer.